ArticleERJ open research2025
Mannitol-evoked cough response is reduced by inhaled salbutamol.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unmet need for biomarkers in chronic cough: a review of current challenges and future directions.ERJ open research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mannitol inhalation induces bronchoconstriction and coughing in asthmatic patients. Salbutamol causes smooth muscle relaxation in acute asthma, but its effects on airway nerves are unclear. We conducted mannitol cough challenges in allergic asthmatic patients (AAs) and healthy controls (HCs) to determine whether salbutamol would reduce mannitol-evoked coughs independent of changes in airway calibre. Methods: A double-blind, randomised, placebo-controlled, two-way crossover study included 20 mild steroid-naïve AAs and 20 HCs. The maximum number of coughs (Emax) evoked by mannitol was compared between salbutamol and placebo. Results: HCs and AAs were matched for age, lung function and sex. Mannitol-evoked cough dose ratio (CDR) in HCs was significantly lower than in AAs (5.63±1.84 Conclusion: Salbutamol reduced mannitol Emax in AAs and HCs. The reduced mannitol-evoked cough response by salbutamol in HCs was independent of changes in airway calibre measured by FEV
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.